Obagi Medical Acquires Novaestiq to Introduce HA Injectables in US Market

Obagi Medical is set to expand into aesthetic injectables following the acquisition of Novaestiq Corp., the company behind the Saypha® ChIQ™ and Saypha® MagIQ™ hyaluronic acid (HA) filler products. The transaction was completed by Obagi’s parent company, Waldencast plc, and marks a significant strategic move as Obagi enters the US injectable market.

Novaestiq, a joint venture formed by Croma-Pharma GmbH and Gore Range Capital, was established to bring Croma-Pharma’s Saypha® line of HA-based fillers to the US The injectables are currently under FDA review, with a clinical development program described as exceeding industry norms in both size and demographic diversity.

Obagi Medical, best known for its topical skin care products, will now add injectable HA fillers to its portfolio. The Saypha® products will be marketed under the Obagi Medical brand upon approval, marking the brand’s first entry into the minimally invasive aesthetics segment.

“This partnership is a testament to the strength of our innovation pipeline and our ability to collaborate with visionary partners,” said Andreas Prinz, CEO of Croma-Pharma GmbH.

Croma-Pharma has more than four decades of experience with HA technology and has manufactured over 110 million syringes to date. Its Saypha® fillers are approved in more than 80 countries and are known for their safety profile and clinical performance.

The acquisition underscores Obagi’s strategy to broaden its clinical offerings in dermatology and aesthetic medicine, positioning the company to compete in the growing US filler market. Further updates on regulatory milestones are anticipated as the FDA review process continues.